-
A 68-year-old white female presented to her internist complaining of fatigue for the past month. The patient is a piano teacher who traveled to her students' houses for their lessons, which had become a significant effort for her.
-
Results from a Phase 3 study of dabigatran, intensive lipid-lowering in CVD, H1N1 vaccine dosing and efficacy, and FDA Actions
-
In a retrospective review of 71 patients treated in either a second- or third-line setting for small-cell lung cancer (SCLC) at a single institution, three orally administered drugs (lomustine, etoposide, and cyclophosphamide) were shown to be effective in producing responses (overall response rate 38%) but had little effect on overall survival (median survival 19 weeks).
-
Among funeral workers, the duration of embalming practice and related formaldehyde exposure were significantly associated with an increased risk for mortality from myeloid leukemia.
-
-
In this pooled analysis of more than 7700 ovarian cancer patients and nearly 12,000 controls, low dose aspirin and high dose non-aspirin NSAID use was associated with a risk reduction for invasive epithelial ovarian cancer of 20 to 34% relative to non-users.
-
In a nested, case-control analysis using a large computerized clinical dataset, a 16% reduction in colorectal cancer incidence was observed after 3 or more years of angiotensin inhibitor and/or angiotensin receptor blocker treatment of hypertension.
-
After a median follow-up of 5 years, the aromatase inhibitor, anastrozole decreased the incidence of breast cancer in high-risk postmenopausal women by 53% compared to women receiving a placebo.
-
Synopsis: In this study, the authors evaluated and refined previously published risk stratification for locoregional failure (LF) by applying it to a multicenter patient cohort.
-
In a trial comparing chemotherapy alone to chemotherapy plus bevacizumab in the treatment of patients with platinium-resistant ovarian cancer, the combination resulted in improved response rates and progression-free survival (PFS) and without a high rate of added toxicity. Whether bevacizumab alone would provide comparable improvements was not assessed but remains an important question for future trials.
